Status:
COMPLETED
Pharmacokinetics of Cidofovir During Continuous Venovenous Hemofiltration
Lead Sponsor:
Medical University of Vienna
Collaborating Sponsors:
University of Vienna
Conditions:
Cytomegalovirus Retinitis
Acute Renal Failure
Eligibility:
MALE
18-75 years
Phase:
PHASE4
Brief Summary
Cidofovir is an acyclic nucleotide analog with broad-spectrum antiviral activity against herpesviruses. Its potency in inhibiting HCMV has been shown in conventional in vitro studies. It is approved f...
Eligibility Criteria
Inclusion
- Age 18 to 75 years
- Suspected of proven HCMV infection
- Suspected or proven resistancy of HCMV to the first line therapy (ganciclovir / foscarnet).
- Continuous venovenous hemodiafiltration (CVVHDF) due to acute or chronic renal failure.
Exclusion
- Known history of hypersensitivity to cidofovir or probenecid.
- An expected survival of less than three days.
- Known alcohol dependency, epilepsy, pregnancy or liver failure.
- Infection with a ganciclovir or foscarnet susceptible HCMV strain
Key Trial Info
Start Date :
March 1 2002
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2002
Estimated Enrollment :
1 Patients enrolled
Trial Details
Trial ID
NCT01866397
Start Date
March 1 2002
End Date
March 1 2002
Last Update
June 5 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Medical University of Vienna
Vienna, Austria, 1190